These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 10231143

  • 1. Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD).
    Kulkarni S, Rodriguez M, Lafuente A, Mateos P, Mehta J, Singhal S, Saso R, Tait D, Treleaven JG, Powles RL.
    Bone Marrow Transplant; 1999 Apr; 23(8):803-7. PubMed ID: 10231143
    [Abstract] [Full Text] [Related]

  • 2. Time-related changes in the incidence, severity, and clinical outcome of hepatic veno-occlusive disease in hematopoietic stem cell transplantation patients during the past 10 years.
    Kalayoglu-Besisik S, Yenerel MN, Caliskan Y, Ozturk S, Besisik F, Sargin D.
    Transplant Proc; 2005 Jun; 37(5):2285-9. PubMed ID: 15964400
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Successful treatment of veno-occlusive disease with recombinant tissue plasminogen activator in a patient requiring peritoneal dialysis.
    Simpson DR, Browett PJ, Doak PB, Palmer SJ.
    Bone Marrow Transplant; 1994 Oct; 14(4):635-6. PubMed ID: 7858540
    [Abstract] [Full Text] [Related]

  • 6. Hepatic veno-occlusive disease after tranexamic acid administration in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Mori T, Aisa Y, Shimizu T, Yamazaki R, Mihara A, Yajima T, Hibi T, Ikeda Y, Okamoto S.
    Am J Hematol; 2007 Sep; 82(9):838-9. PubMed ID: 17506069
    [Abstract] [Full Text] [Related]

  • 7. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
    Cesaro S, Pillon M, Talenti E, Toffolutti T, Calore E, Tridello G, Strugo L, Destro R, Gazzola MV, Varotto S, Errigo G, Carli M, Zanesco L, Messina C.
    Haematologica; 2005 Oct; 90(10):1396-404. PubMed ID: 16219577
    [Abstract] [Full Text] [Related]

  • 8. Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study.
    Tanikawa S, Mori S, Ohhashi K, Akiyama H, Sasaki T, Kaku H, Hiruma K, Matsunaga T, Morita T, Sakamaki H.
    Bone Marrow Transplant; 2000 Oct; 26(8):881-6. PubMed ID: 11081389
    [Abstract] [Full Text] [Related]

  • 9. Hepatic veno-occlusive disease with severe capillary leakage after peripheral stem cell transplantation: treatment with recombinant plasminogen activator and C1-esterase inhibitor concentrate.
    Heying R, Nürnberger W, Spiekerkötter U, Göbel U.
    Bone Marrow Transplant; 1998 May; 21(9):947-9. PubMed ID: 9613790
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Treatment of hepatic veno-occlusive disease after bone marrow transplantation with recombinant human tissue plasminogen activator (rh-tPA)].
    Yoshimi A, Kato K, Maeda N, Matsuyama T, Kojima S.
    Rinsho Ketsueki; 2000 Feb; 41(2):103-8. PubMed ID: 10723238
    [Abstract] [Full Text] [Related]

  • 12. Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation.
    Toh HC, McAfee SL, Sackstein R, Cox BF, Colby C, Spitzer TR.
    Bone Marrow Transplant; 1999 Oct; 24(8):891-5. PubMed ID: 10516702
    [Abstract] [Full Text] [Related]

  • 13. Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation.
    Cheuk DK, Wang P, Lee TL, Chiang AK, Ha SY, Lau YL, Chan GC.
    Bone Marrow Transplant; 2007 Nov; 40(10):935-44. PubMed ID: 17768390
    [Abstract] [Full Text] [Related]

  • 14. Successful treatment of hepatic veno-occlusive disease after myeloablative allogeneic hematopoietic stem cell transplantation by early administration of a short course of methylprednisolone.
    Al Beihany A, Al Omar H, Sahovic E, Chaudhri N, Al Mohareb F, Al Sharif F, Al Zahrani H, Al Shanqeeti A, Seth P, Zaidi S, Morshed M, Al Anazi K, Mohamed G, Gyger M, Aljurf M.
    Bone Marrow Transplant; 2008 Feb; 41(3):287-91. PubMed ID: 17982501
    [Abstract] [Full Text] [Related]

  • 15. Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation.
    Schriber J, Milk B, Shaw D, Christiansen N, Baer M, Slack J, Tezcan H, Wetzler M, Herzig G.
    Bone Marrow Transplant; 1999 Dec; 24(12):1311-4. PubMed ID: 10627640
    [Abstract] [Full Text] [Related]

  • 16. Treatment of hepatic veno-occlusive disease with low-dose tissue plasminogen activator: impact on coagulation profile.
    Goldberg SL, Shubert J, Rao AK, Redei I, Klumpp TR, Mangan KF.
    Bone Marrow Transplant; 1996 Sep; 18(3):633-6. PubMed ID: 8879629
    [Abstract] [Full Text] [Related]

  • 17. Recombinant tissue plasminogen activator (rTPA) for hepatic veno-occlusive disease after allogeneic BMT in a pediatric patient.
    Feldman L, Gabai E, Milovic V, Jaimovich G.
    Bone Marrow Transplant; 1995 Nov; 16(5):727. PubMed ID: 8547875
    [No Abstract] [Full Text] [Related]

  • 18. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation.
    Chalandon Y, Roosnek E, Mermillod B, Newton A, Ozsahin H, Wacker P, Helg C, Chapuis B.
    Biol Blood Marrow Transplant; 2004 May; 10(5):347-54. PubMed ID: 15111934
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.